Results from two studies of Eli Lilly’s solanezumab suggested it may slow mental decline, but doctors said another study was probably necessary for federal approval.img width='1' height='1' src='http://rss.nytimes.com/c/34625/f/640346/s/24438703/mf.gif' border='0'/br/br/a href="http://da.feedsportal.com/r/146821121934/u/0/f/640346/c/34625/s/24438703/a2.htm"img src="http://da.feedsportal.com/r/146821121934/u/0/f/640346/c/34625/s/24438703/a2.img" border="0"//aimg width="1" height="1" src="http://pi.feedsportal.com/r/146821121934/u/0/f/640346/c/34625/s/24438703/a2t.img" border="0"/